引用Crémieux (@cremieuxrecueil)@cremieuxrecueil
This is actually insane. 97% of people taking the standard of care for metastatic solid tumor got worse by seven years. But with lorlatinib, that number was only 45% in the same time! This is an ENORMOUS jump in the quality of cancer care.